Skip to main content
Pfizer Inc. (LON:0Q1N)
London flag London · Delayed Price · Currency is GBP · Price in USD
24.08
0.00 (0.00%)
At close: May 2, 2025

Revenue by Product

Financial numbers in millions USD.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Oncology
15,612
Log In
Log In
Log In
Log In
Oncology Growth
25.40%
Log In
Log In
Log In
Log In
Business Innovation (Pfizer CentreOne)
1,146
Log In
Log In
Log In
Log In
Business Innovation (Pfizer CentreOne) Growth
-9.91%
Log In
Log In
Log In
Log In
Global Pharmaceuticals Business (Biopharma)
62,400
Log In
Log In
Log In
Log In
Global Pharmaceuticals Business (Biopharma) Growth
7.15%
Log In
Log In
Log In
Log In
Primary Care
30,135
Log In
Log In
Log In
Log In
Primary Care Growth
-2.16%
Log In
Log In
Log In
Log In
Specialty Care
16,652
Log In
Log In
Log In
Log In
Specialty Care Growth
11.11%
Log In
Log In
Log In
Log In

Other

Financial numbers in millions USD.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
United States Revenue
38,691
Log In
Log In
Log In
Log In
United States Revenue Growth
37.47%
Log In
Log In
Log In
Log In
Developed Europe Revenue
-
Log In
Log In
Log In
Log In
Developed Europe Revenue Growth
-
Log In
Log In
Log In
Log In
Developed Rest of World Revenue
-
Log In
Log In
Log In
Log In
Developed Rest of World Revenue Growth
-
Log In
Log In
Log In
Log In
Emerging Markets Revenue
-
Log In
Log In
Log In
Log In
Emerging Markets Revenue Growth
-
Log In
Log In
Log In
Log In
International Revenue
24,936
Log In
Log In
Log In
Log In
International Revenue Growth
-20.60%
Log In
Log In
Log In
Log In
Developed Markets Revenue
16,057
Log In
Log In
Log In
Log In
Developed Markets Revenue Growth
-23.21%
Log In
Log In
Log In
Log In
Emerging Markets Revenue (Post-FY2023 Reporting)
8,879
Log In
Log In
Log In
Log In
Emerging Markets Revenue (Post-FY2023 Reporting) Growth
-15.41%
Log In
Log In
Log In
Log In
Global Pharmaceuticals Business (Biopharma) Earnings
28,139
Log In
Log In
Log In
Log In
Global Pharmaceuticals Business (Biopharma) Earnings Growth
319.79%
Log In
Log In
Log In
Log In
Other Business Activities Earnings
-7,382
Log In
Log In
Log In
Log In
Other Business Activities Earnings Growth
83.19%
Log In
Log In
Log In
Log In
Prevnar Revenue
-
Log In
Log In
Log In
Log In
Prevnar Revenue Growth
-
Log In
Log In
Log In
Log In
Xeljanz Revenue
1,168
Log In
Log In
Log In
Log In
Xeljanz Revenue Growth
-31.37%
Log In
Log In
Log In
Log In
Vaccines Revenue
-
Log In
Log In
Log In
Log In
Vaccines Revenue Growth
-
Log In
Log In
Log In
Log In
Ibrance Revenue
4,367
Log In
Log In
Log In
Log In
Ibrance Revenue Growth
-8.14%
Log In
Log In
Log In
Log In
Internal Medicine Revenue
-
Log In
Log In
Log In
Log In
Internal Medicine Revenue Growth
-
Log In
Log In
Log In
Log In
Inflammation & Immunology Revenue
-
Log In
Log In
Log In
Log In
Inflammation & Immunology Revenue Growth
-
Log In
Log In
Log In
Log In
Rare Disease Revenue
-
Log In
Log In
Log In
Log In
Rare Disease Revenue Growth
-
Log In
Log In
Log In
Log In
Eliquis Alliance Revenue and Direct Sales
7,366
Log In
Log In
Log In
Log In
Eliquis Alliance Revenue and Direct Sales Growth
9.19%
Log In
Log In
Log In
Log In
Vyndaqel Revenue
5,451
Log In
Log In
Log In
Log In
Vyndaqel Revenue Growth
64.14%
Log In
Log In
Log In
Log In
Hospital Revenue
-
Log In
Log In
Log In
Log In
Hospital Revenue Growth
-
Log In
Log In
Log In
Log In
Comirnaty Direct Sales and Alliance Revenue
5,353
Log In
Log In
Log In
Log In
Comirnaty Direct Sales and Alliance Revenue Growth
-52.28%
Log In
Log In
Log In
Log In
Paxlovid Revenue
5,716
Log In
Log In
Log In
Log In
Paxlovid Revenue Growth
346.91%
Log In
Log In
Log In
Log In
Prevnar Family Revenue
6,411
Log In
Log In
Log In
Log In
Prevnar Family Revenue Growth
-1.37%
Log In
Log In
Log In
Log In
Nurtec ODT/Vydura Revenue
1,263
Log In
Log In
Log In
Log In
Nurtec ODT/Vydura Revenue Growth
35.95%
Log In
Log In
Log In
Log In
Abrysvo Revenue
755
Log In
Log In
Log In
Log In